A leader in Molecular Imaging CDx for
targeted therapies in Oncology
Zionexa, a spin-off of Cyclopharma, combines proven heritage with a pioneering approach to deliver innovation, excellence and unparalleled service.
COMPANION DIAGNOSTICS (CDx)
We are dedicated to developing CDx to guide targeted therapies for precision medicine. CDx ensures a personal diagnosis for every patient, a selection of an effective treatment, as well as a therapy monitoring.
Molecular Imaging (MI) is a non-invasive technique which allows healthcare professionals to visualize molecules and their function within the cell. MI is used for initial diagnosis and monitoring of cancer tumors.
We are driven by the fact that cancer is a leading cause of death worldwide, accounting for 8.8 million deaths in 2015. Everyday, we work to develop biomarkers specialized in oncology to improve the patient’s pathway and quality of life.
Our team is composed of international experts who have more than 20 years of experience in radiopharmaceutical industry and Molecular Imaging.